There is one clinical trial.
Low dose whole lung radiotherapy may improve survival of older patients with COVID-19 pneumonitis
Description: Comparing mortality rate of the whole group of patients treated with low dose whole lung radiotherapy with historical dataMeasure: Mortality rate Time: One year
Description: Comparison mortality rate of different ethnic groups treated with whole lung radiotherapy for COVID-19 pneumoniaMeasure: Mortality rate Time: One year
Description: Duration of hospitalization for the whole group and different groups with or without oxygen requirementMeasure: Duration of hospitalization Time: One year
Description: Ordinal scale at the time of radiotherapy and 28 days laterMeasure: Time to recovery Time: One month
Description: Correlation between oxygen saturation rate and ordinal scale at different times following radiotherapyMeasure: Oxygen saturation rate Time: One year
Description: Biomarkers for inflammation such as Interleukin 6 will be monitored and correlated with ordinal scale at different times following radiotherapyMeasure: Patient inflammatory status Time: One year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports